1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators evaluated the effect of pre-biopsy treatment with 1-deamino-8-D-arginine (DDAVP) on the incidence of post-biopsy bleeding complications. This is a IV phase single centre, double blind, randomized controlled study in patients, with acute and chronic nephropathy, undergoing ultrasound-guided percutaneous renal biopsy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Bari
• Treatments: Arginine Vasopressin; Deamino Arginine Vasopressin; Pharmaceutical Solutions; Vasopressins

Criteria

Inclusion Criteria:

1. Males or females > 16 and < 80 years of age.

2. Blood pressure < 140/90 mmHg.

3. Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ≥ 60 ml/min.

4. Bleeding time, prothrombin time, partial thromboplastin time, platelets and fibrinogen in the normal range.

Exclusion Criteria:

1. Biopsy of transplant kidney

2. Poorly controlled hypertension

3. Single kidney

4. Renal cancer

5. Hydro/pyonephrosis

6. Renal size significantly reduced

7. Severe obesity

8. Coagulation disorder

9. Serum creatinine > 1.5 mg/dl and/or creatinine clearance < 60 ml/min